Assessment of Adverse Drug Reactions in Patients on Cardiovascular Drugs: A Prospective Study
Objectiv: To quantify ADRs in patients on cardiovascular drugs and to assess their severity. Materials and Methods: Based on inclusion and exclusion criteria, 265 inpatients on cardiovascular drugs from a tertiary care center were included in this prospective study. All patients were assessed for oc...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmacology & pharmacotherapeutics 2020-04, Vol.11 (2), p.59-63 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 63 |
|---|---|
| container_issue | 2 |
| container_start_page | 59 |
| container_title | Journal of pharmacology & pharmacotherapeutics |
| container_volume | 11 |
| creator | Sneha, C. Anuradha, H. V. Karthik, Ashok |
| description | Objectiv: To quantify ADRs in patients on cardiovascular drugs and to assess their severity. Materials and Methods: Based on inclusion and exclusion criteria, 265 inpatients on cardiovascular drugs from a tertiary care center were included in this prospective study. All patients were assessed for occurrence of ADR and followed up till the recovery of the ADR. Causality assessment of ADR was done, severity of ADR was graded, and preventability of ADR was assessed. Results: In the present study, descriptive statistics were used to analyze the data. Out of 265 patients screened, 137 (51.69%) had 245 ADRs. About 175 (71%) ADRs were due to antihypertensives, 175 (71%). On causality assessment of these ADRs, 230 (94%) were found to be possible and 15 (6%) probable. Two hundred and nine (85%) ADRs were mild, 34 (14%) were moderate, and 2 (1%) were severe. The most common ADR encountered in the study was giddiness due to various classes of antihypertensives in 26% about patients. Conclusions: Among the cardiovascular system drugs, antihypertensives were the most common group of drugs to cause giddiness as ADR. Majority of the ADRs had a score of "possible" because of concomitant medications. |
| doi_str_mv | 10.4103/jpp.JPP_106_19 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2532819420</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A639963840</galeid><sage_id>10.4103_jpp.JPP_106_19</sage_id><sourcerecordid>A639963840</sourcerecordid><originalsourceid>FETCH-LOGICAL-g373e-740155c8415293e27b7a9a41a1c0c12e531b92fa6288366086b605192cec83363</originalsourceid><addsrcrecordid>eNptkdtLIzEUxgdRUNRXnwOCL9Kay0xmsi_LUC-7UrB4AV-WkGbO1KnTSc2Zadn_flOrWwuePJwQft93yPmi6ITRfsyouJjO5_3b0UgzKjVTO9EBVansJZRlu__v9Hk_Okac0lBCxTRWB9GfHBEQZ9C0xJUkLxbgEcil7ybkHoxtK9cgqRoyMm0VICSuIQPji8otDNquNv4dxh8kJyPvcA5BswDy0HbF36NorzQ1wvFHP4yerq8eB796w7ub34N82JuIVEAvjSlLEpvFLOFKAE_HqVEmZoZZahmHRLCx4qWRPMuElDSTY0kTprgFmwkhxWF0uvade_fWAbZ66jrfhJGaJ4JnTMWcbqiJqUFXTelab-ysQqtzKZSSIotXVP8bKpwCZpV1DZRVeN8SnH0RvICp2xd0dfe-um3w5xpcuroNa36tuyV4PYPitXHLEJ1eRalDlHoTpU6U_swoOJyvHdBMYPPH75XiH3zEocQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532819420</pqid></control><display><type>article</type><title>Assessment of Adverse Drug Reactions in Patients on Cardiovascular Drugs: A Prospective Study</title><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sneha, C. ; Anuradha, H. V. ; Karthik, Ashok</creator><creatorcontrib>Sneha, C. ; Anuradha, H. V. ; Karthik, Ashok</creatorcontrib><description>Objectiv: To quantify ADRs in patients on cardiovascular drugs and to assess their severity. Materials and Methods: Based on inclusion and exclusion criteria, 265 inpatients on cardiovascular drugs from a tertiary care center were included in this prospective study. All patients were assessed for occurrence of ADR and followed up till the recovery of the ADR. Causality assessment of ADR was done, severity of ADR was graded, and preventability of ADR was assessed. Results: In the present study, descriptive statistics were used to analyze the data. Out of 265 patients screened, 137 (51.69%) had 245 ADRs. About 175 (71%) ADRs were due to antihypertensives, 175 (71%). On causality assessment of these ADRs, 230 (94%) were found to be possible and 15 (6%) probable. Two hundred and nine (85%) ADRs were mild, 34 (14%) were moderate, and 2 (1%) were severe. The most common ADR encountered in the study was giddiness due to various classes of antihypertensives in 26% about patients. Conclusions: Among the cardiovascular system drugs, antihypertensives were the most common group of drugs to cause giddiness as ADR. Majority of the ADRs had a score of "possible" because of concomitant medications.</description><identifier>ISSN: 0976-500X</identifier><identifier>EISSN: 0976-5018</identifier><identifier>DOI: 10.4103/jpp.JPP_106_19</identifier><language>eng</language><publisher>New Delhi, India: SAGE Publications</publisher><subject>Analysis ; Antihypertensives ; Cardiac patients ; Causality ; Cilostazol ; Clopidogrel ; Drug therapy ; Drugs ; Hospital patients ; Ivabradine ; Medical research ; Patient compliance ; Telmisartan ; Torsemide</subject><ispartof>Journal of pharmacology & pharmacotherapeutics, 2020-04, Vol.11 (2), p.59-63</ispartof><rights>2020 The Authors</rights><rights>COPYRIGHT 2020 Medknow Publications and Media Pvt. Ltd.</rights><rights>2020. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.4103/jpp.JPP_106_19$$EPDF$$P50$$Gsage$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.4103/jpp.JPP_106_19$$EHTML$$P50$$Gsage$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,21965,27852,27923,27924,44944,45332</link.rule.ids></links><search><creatorcontrib>Sneha, C.</creatorcontrib><creatorcontrib>Anuradha, H. V.</creatorcontrib><creatorcontrib>Karthik, Ashok</creatorcontrib><title>Assessment of Adverse Drug Reactions in Patients on Cardiovascular Drugs: A Prospective Study</title><title>Journal of pharmacology & pharmacotherapeutics</title><description>Objectiv: To quantify ADRs in patients on cardiovascular drugs and to assess their severity. Materials and Methods: Based on inclusion and exclusion criteria, 265 inpatients on cardiovascular drugs from a tertiary care center were included in this prospective study. All patients were assessed for occurrence of ADR and followed up till the recovery of the ADR. Causality assessment of ADR was done, severity of ADR was graded, and preventability of ADR was assessed. Results: In the present study, descriptive statistics were used to analyze the data. Out of 265 patients screened, 137 (51.69%) had 245 ADRs. About 175 (71%) ADRs were due to antihypertensives, 175 (71%). On causality assessment of these ADRs, 230 (94%) were found to be possible and 15 (6%) probable. Two hundred and nine (85%) ADRs were mild, 34 (14%) were moderate, and 2 (1%) were severe. The most common ADR encountered in the study was giddiness due to various classes of antihypertensives in 26% about patients. Conclusions: Among the cardiovascular system drugs, antihypertensives were the most common group of drugs to cause giddiness as ADR. Majority of the ADRs had a score of "possible" because of concomitant medications.</description><subject>Analysis</subject><subject>Antihypertensives</subject><subject>Cardiac patients</subject><subject>Causality</subject><subject>Cilostazol</subject><subject>Clopidogrel</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Hospital patients</subject><subject>Ivabradine</subject><subject>Medical research</subject><subject>Patient compliance</subject><subject>Telmisartan</subject><subject>Torsemide</subject><issn>0976-500X</issn><issn>0976-5018</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkdtLIzEUxgdRUNRXnwOCL9Kay0xmsi_LUC-7UrB4AV-WkGbO1KnTSc2Zadn_flOrWwuePJwQft93yPmi6ITRfsyouJjO5_3b0UgzKjVTO9EBVansJZRlu__v9Hk_Okac0lBCxTRWB9GfHBEQZ9C0xJUkLxbgEcil7ybkHoxtK9cgqRoyMm0VICSuIQPji8otDNquNv4dxh8kJyPvcA5BswDy0HbF36NorzQ1wvFHP4yerq8eB796w7ub34N82JuIVEAvjSlLEpvFLOFKAE_HqVEmZoZZahmHRLCx4qWRPMuElDSTY0kTprgFmwkhxWF0uvade_fWAbZ66jrfhJGaJ4JnTMWcbqiJqUFXTelab-ysQqtzKZSSIotXVP8bKpwCZpV1DZRVeN8SnH0RvICp2xd0dfe-um3w5xpcuroNa36tuyV4PYPitXHLEJ1eRalDlHoTpU6U_swoOJyvHdBMYPPH75XiH3zEocQ</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Sneha, C.</creator><creator>Anuradha, H. V.</creator><creator>Karthik, Ashok</creator><general>SAGE Publications</general><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20200401</creationdate><title>Assessment of Adverse Drug Reactions in Patients on Cardiovascular Drugs: A Prospective Study</title><author>Sneha, C. ; Anuradha, H. V. ; Karthik, Ashok</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g373e-740155c8415293e27b7a9a41a1c0c12e531b92fa6288366086b605192cec83363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Analysis</topic><topic>Antihypertensives</topic><topic>Cardiac patients</topic><topic>Causality</topic><topic>Cilostazol</topic><topic>Clopidogrel</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Hospital patients</topic><topic>Ivabradine</topic><topic>Medical research</topic><topic>Patient compliance</topic><topic>Telmisartan</topic><topic>Torsemide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sneha, C.</creatorcontrib><creatorcontrib>Anuradha, H. V.</creatorcontrib><creatorcontrib>Karthik, Ashok</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of pharmacology & pharmacotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sneha, C.</au><au>Anuradha, H. V.</au><au>Karthik, Ashok</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of Adverse Drug Reactions in Patients on Cardiovascular Drugs: A Prospective Study</atitle><jtitle>Journal of pharmacology & pharmacotherapeutics</jtitle><date>2020-04-01</date><risdate>2020</risdate><volume>11</volume><issue>2</issue><spage>59</spage><epage>63</epage><pages>59-63</pages><issn>0976-500X</issn><eissn>0976-5018</eissn><abstract>Objectiv: To quantify ADRs in patients on cardiovascular drugs and to assess their severity. Materials and Methods: Based on inclusion and exclusion criteria, 265 inpatients on cardiovascular drugs from a tertiary care center were included in this prospective study. All patients were assessed for occurrence of ADR and followed up till the recovery of the ADR. Causality assessment of ADR was done, severity of ADR was graded, and preventability of ADR was assessed. Results: In the present study, descriptive statistics were used to analyze the data. Out of 265 patients screened, 137 (51.69%) had 245 ADRs. About 175 (71%) ADRs were due to antihypertensives, 175 (71%). On causality assessment of these ADRs, 230 (94%) were found to be possible and 15 (6%) probable. Two hundred and nine (85%) ADRs were mild, 34 (14%) were moderate, and 2 (1%) were severe. The most common ADR encountered in the study was giddiness due to various classes of antihypertensives in 26% about patients. Conclusions: Among the cardiovascular system drugs, antihypertensives were the most common group of drugs to cause giddiness as ADR. Majority of the ADRs had a score of "possible" because of concomitant medications.</abstract><cop>New Delhi, India</cop><pub>SAGE Publications</pub><doi>10.4103/jpp.JPP_106_19</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0976-500X |
| ispartof | Journal of pharmacology & pharmacotherapeutics, 2020-04, Vol.11 (2), p.59-63 |
| issn | 0976-500X 0976-5018 |
| language | eng |
| recordid | cdi_proquest_journals_2532819420 |
| source | Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals |
| subjects | Analysis Antihypertensives Cardiac patients Causality Cilostazol Clopidogrel Drug therapy Drugs Hospital patients Ivabradine Medical research Patient compliance Telmisartan Torsemide |
| title | Assessment of Adverse Drug Reactions in Patients on Cardiovascular Drugs: A Prospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T23%3A07%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20Adverse%20Drug%20Reactions%20in%20Patients%20on%20Cardiovascular%20Drugs:%20A%20Prospective%20Study&rft.jtitle=Journal%20of%20pharmacology%20&%20pharmacotherapeutics&rft.au=Sneha,%20C.&rft.date=2020-04-01&rft.volume=11&rft.issue=2&rft.spage=59&rft.epage=63&rft.pages=59-63&rft.issn=0976-500X&rft.eissn=0976-5018&rft_id=info:doi/10.4103/jpp.JPP_106_19&rft_dat=%3Cgale_proqu%3EA639963840%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2532819420&rft_id=info:pmid/&rft_galeid=A639963840&rft_sage_id=10.4103_jpp.JPP_106_19&rfr_iscdi=true |